Parkinson's, Headache, Dementia Flashcards
neuroanatomical and neurochemical processes leading to parkinsons
dopamine deficiency
loss of dopaminergic cells
formation of lewy bodies
main symptoms of parkinsons
bradykinesia, rigidity, resting tremor, postural instability
slowness and difficulty initiating voluntary movement
bradykinesia
resistance to passive range of motion
rigidity
occurs at rest abolished by movement but can progress to action
tremor
motor symptoms of parkinsons
freezing, slow turning, decreased dexterity
MOA of benztropine & trihexyphenidyl
anticholinergic- blocks acetylcholine at muscarinic receptors
AEs of anticholinergics
possible link to cognitive impairment and decline***
mydriasis, dry mouth/skin, urinary retention, constipation, fever, mental change, flushed skin
gold standard for parkinsons treatment that is a building block of dopamine
levodopa
contraindications to l-dopa
breastfeeding, closed angle glaucoma, melanoma
dopa-decarboxylase inhibitor that blocks peripheral l-dopa metabolism and is always given with l-dopa
carbidopa
AEs of l-dopa
dopaminergic CNS/GI
dyskinesia, on-off, decreased effect w/ time, psych disturbances, vivid dreams, nausea, orthostatic hypotension, falls, urine/sweat/saliva discoloration, NMS w/ abrupt d/c (taper)
DDIs of l-dopa
da antagonists, nonselective maois, high protein, iron salts, b6
carbidopa dose needs to be maintained at what per day
at least 70-100 mg/day
onset of effect with ER sinemet is
delayed
intestinal gel form of l-dopa
duopa
powder for inhalation form of l-dopa
Inbrija
AEs of inbrija
blackens saliva and nasal secretions **
somnolence, hallucinations, dyskinesia, cough, URTI, nausea
when is inbrija not recommended
asthma, COPD, other lung disease
contraindications of inbrija
nonselective maoi within 2 weeks
when is inbrija used
intermittent for off episodes, DOES NOT REPLACE PO
reversible selective inhibitors of COMT that prevent breakdown of l-dopa and extend its effects
entacapone, tolcapone, opicapone
are COMT inhibitors monotherapy or adjust
ADJUNCT ONLY- no effect in absence of L-dopa
DDIs with COMT inhibitors
nonselective MAOIs*, drugs metabolized by COMT
when is entacapone administered
with each dose up carb/levo up to 8x a day
AE of entacapone
brown/orange urine
major AE/CI of tolcapone
risk for hepatocellular injury
CI with hepatic disease
opicapone dosing
once daily QHS
how is opicapone absorption affected by food
decreased absorption with high fat/calorie meals
noncompetitive, selective antagonists of MAO-B that decrease breakdown of DA and free radical production
selegiline
rasagiline
safinamide (xadago)
AEs of selegiline
insomnia, jitteriness*
HA, dopaminergic, HTN crisis, serotonin syndrome, etc.
caution with MAOI-B agents and foods containing
tyramine
is selegiline mono or adjunct
labeled adjunct, can be mono early
which MAO-B has 3 active amphetamine metabolites
selegiline
which MAO-B can be disease modifying
rasagiline
is rasagiline mono or adjunct
either
AEs of rasagiline
orthostasis, dopaminergic, HA, arthralgia, GI
most MAO-B agents have DDI with
nonspecific MAOIs, serotonergic drugs, sympathomimetics, tyramine foods
is safinamide (xadago) mono or adjunct
adjunct for wearing off
AEs of safinamide
dopaminergic, daytime somnolence, withdrawal NMS syndrome, retinal
CI to safinamide
child pugh C
agents that directly activate post synaptic DA receptors
pramiprexole
ropinrole
rotigotine
apomorphine
are DA agonists mono or adjunct
mono in healthy/young patients, or adjunct in case of deterioration in response to L-dopa
which type of AEs are more common with dopamine agonists? examples? in who?
nonmotor in older/frail
impulsive behaviors, psychosis, vivid dreams, daytime sedation
major DI of ropinrole with substrates of
CYP1A2
CI of ropinrole
abrupt d/c, hepatic disease
route of admin of rotigotine (neupro)
patch
rotigotine AEs
CNS, GI, peripheral edema, application site rxn*
caution with what when using rotigotine
heat & MRIs, allergy potential
when is apomorphine used
advanced PD PRN adjunctive treatment if unpredictable off or nonresponsive to other therapy
how is apomorphine initiated
test dose under supervision pretreated with an antiemetic
major DDI/CI of apomorphine
5HT3 antagonists increase hypotensive effects
AEs of apomorphine
dopaminergic, dizziness, falls, somnolence, chest pain
agent with poorly understood mechanism that increases endogenous DA
amantadine
effects of amantadine
decreases l-dopa induced dyskinesia*, and other parkinsons sx
ER amantadine (Gocovri) is only indicated for
l-dopa induced dyskinesia
amantadine needs dose adjustment for
renal impairment
AEs of amantadine
orthostatic hypotension, dizzy, falls, hallucinations, etc.